F-star Therapeutics, Inc.
FSTXDelisted Mar 9, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001566373
F-star Therapeutics, Inc. was delisted on Mar 9, 2023; its insiders filed their last Form 4 on Mar 9, 2023; 59 institutions reported holding it in 13F filings for Q4 2022, worth $57.8M in total; Fairfax Financial was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:32 PM ET
Revenue flow, FY2021
Where the revenue went in FY2021, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2021: $31.3M (147.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 14, 2022 | Mar 29, 2021 | Jan 29, 2020 | – | – |
| Revenue | $21.2M | $11.3M | – | – | – |
| Research and development | $28.8M | $14.1M | $23.3M | $19.8M | $13.1M |
| Selling, general and administrative | $23.1M | $19.5M | $9.75M | $8.72M | $8.18M |
| Operating income | -$30.7M | -$22.4M | -$33.0M | -$28.5M | -$21.3M |
| Interest expense | $844.0K | – | $542.0K | – | – |
| Income tax | -$372.0K | -$1.00K | $0 | $0 | $0 |
| Net income | -$31.3M | -$25.6M | -$24.1M | -$22.9M | -$27.7M |
| EPS, basic | – | – | $-1.46 | $-1.59 | – |
| EPS, diluted | – | – | $-1.46 | $-1.88 | – |
| Weighted shares, basic | – | – | 16.5M | 14.4M | – |
| Weighted shares, diluted | – | – | 16.5M | 14.6M | – |
| Margins and growth | |||||
| Operating margin | -145.1% | -198.9% | – | – | – |
| Net margin | -147.8% | -227.6% | – | – | – |
| Revenue growth, year over year | +88.1% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 14, 2022 | Mar 29, 2021 | Jan 29, 2020 | – | – |
| Cash and equivalents | $78.5M | $18.5M | $28.7M | $14.7M | $23.6M |
| Short-term investments | – | – | $25.7M | $32.9M | $26.9M |
| Total current assets | $84.7M | $26.1M | $58.0M | $49.3M | $51.1M |
| Property, plant and equipment | $887.0K | $789.0K | $2.23M | $2.32M | $687.0K |
| Goodwill | $14.9M | $14.9M | – | – | – |
| Intangible assets | $18.8M | $19.0M | – | – | – |
| Total assets | $123.0M | $63.6M | $63.2M | $68.8M | $52.3M |
| Accounts payable | $3.08M | $4.60M | $2.21M | $1.88M | $1.70M |
| Short-term debt | – | $0 | – | – | – |
| Total current liabilities | $12.1M | $17.0M | $5.41M | $4.25M | $4.43M |
| Long-term debt | $9.61M | – | $19.1M | – | – |
| Total liabilities | $26.2M | $20.6M | $27.7M | $13.0M | $17.6M |
| Shareholders' equity | $96.9M | $43.0M | $35.5M | $55.9M | $34.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 14, 2022 | Mar 29, 2021 | Jan 29, 2020 | – | – |
| Operating cash flow | -$27.3M | -$16.2M | -$29.1M | -$25.2M | – |
| Capital expenditures | $658.0K | – | $272.0K | $1.97M | $323.0K |
| Free cash flow | -$27.9M | – | -$29.3M | -$27.2M | – |
| Depreciation and amortization | – | – | $357.0K | $288.0K | $158.0K |
| Stock-based compensation | $6.90M | $3.49M | $3.37M | $2.78M | $1.91M |
| Investing cash flow | -$643.0K | $14.0M | $23.5M | -$25.1M | – |
| Financing cash flow | $88.1M | $15.8M | $19.5M | $41.2M | – |
| Net change in cash | $60.2M | $13.7M | $14.0M | -$9.18M | $13.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 32.6% | 31.0% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Sep 30, 2022 | 22.0M | +6.6% | SEC |
| Jun 30, 2022 | 21.6M | +4.7% | SEC |
| Mar 31, 2022 | 21.5M | +136.2% | SEC |
| Mar 1, 2022 | 21.1M | +131.5% | SEC |
| Nov 8, 2021 | 20.6M | +19.4% | SEC |
| Aug 7, 2021 | 20.6M | +19.5% | SEC |
| May 12, 2021 | 19.4M | +13.3% | SEC |
| Mar 24, 2021 | 9.10M | −46.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.